MLN1117 (INK1117) selectively inhibits PI3K alpha kinase, including mutations of PIK3CA, and therefore, targets the PI3K/Akt/mTOR pathway with potentially less toxicity than pan-PI3K inhibitors (NCI Drug Dictionary).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|MLN1117||INK1117|TAK-117||PIK3CA inhibitor 14||MLN1117 (INK1117) selectively inhibits PI3K alpha kinase, including mutations of PIK3CA, and therefore, targets the PI3K/Akt/mTOR pathway with potentially less toxicity than pan-PI3K inhibitors (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References||KRAS mutant||Advanced Solid Tumor||no benefit||MLN1117||Preclinical||Actionable||In a preclinical study, MLN1117 (INK1117) did not inhibit tumor growth in xenograft models harboring mutations in KRAS (American Association for Cancer Research; 2011:Abstract nr 4501).||detail...||Unknown unknown||breast cancer||not applicable||MLN1117||Phase I||Actionable||In a Phase I trial, treatment with MLN1117 resulted in antitumor activity, demonstrating partial responses in patients with advanced solid tumors including breast and gastric cancer (J Clin Oncol, May 2015 vol. 33 no. 15_suppl 2501).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02551055||Phase I||Docetaxel Paclitaxel Alisertib TAK-659 MLN1117||MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma||Terminated|
|NCT01449370||Phase I||MLN1117||Dose Escalation Study of MLN1117 in Subjects With Advanced Cancer||Completed|